3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
2
Active not recruiting
2
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
14
Gastrointestinal
3
Head & Neck
2
Gynecologic
2
Genitourinary
2
Dermatologic
2
NET
1
Endocrine
1
CNS
1
Breast
1
Conditions
Brain Neoplasms
1050
Glioblastoma
920
Glioma
601
Central Nervous System Neoplasms
436
Astrocytoma
396
Gliosarcoma
339
Neuroblastoma
325
Oligodendroglioma
255
Neoplasms
181
Medulloblastoma
165
Breast Neoplasms
154
Sarcoma
114
Recurrence
108
Ependymoma
105
Neoplasm Metastasis
95
Meningioma
91
Melanoma
88
Lymphoma
87
Carcinoma, Non-Small-Cell Lung
87
Lung Neoplasms
82
Precursor Cell Lymphoblastic Leukemia-Lymphoma
79
Neurofibromatosis 1
78
Wilms Tumor
75
Osteosarcoma
69
Head and Neck Neoplasms
69
Ovarian Neoplasms
68
Testicular Neoplasms
67
Lymphoma, Non-Hodgkin
67
Burkitt Lymphoma
66
Familial ependymoma
63
Interventions
Gefitinib
1
Erlotinib Hydrochloride
1
AZD3759
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Respiratory Tract Diseases
×
CNS
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled